TP53 and acute lymphoblastic leukemia: Unsurprisingly, combination drug therapy of imatinib and nutlin‐3 showed a certain potential to overcome drug resistance in ALL, indicating that p53 could be considered a drug target in imatinib‐resistant Ph+ leukemias.